Biotechnology Market News

Cuba approves first therapeutic vaccine for lung cancer - Tehran Times

Cuba approves first therapeutic vaccine for lung cancer Tehran Times, Iran - 1 hour ago The therapeutic vaccine CimaVax EGF extends life with few side effects, and is another step in Cuba's expertise in biotechnology. It was unveiled on Monday ...

WHO-led Group Unveils New TB Testing Plan - Voice of America

WHO-led Group Unveils New TB Testing Plan Voice of America - 2 hours ago ... to begin converting laboratories in more than two-dozen of the poorest nations from molecular-based testing to genetics testing for tuberculosis. ...

Biotech plans mapped out for Briger tract - Palm Beach Post

Biotech plans mapped out for Briger tract Palm Beach Post,  United States - 3 hours ago Post coverage of the growth in biotechnology in PB County and the TCoast. The so-called Briger tract is vacant land across Donald Ross Road from Florida ...

Save our RICE - Deccan Herald

Save our RICE Deccan Herald, India - 42 minutes ago G Krishna Prasad of Sahaja Samruddha says it is time to understand and appreciate farmers' biotechnology. He further said that farmers, media and scientists ...

Biotech plans mapped out for Briger tract - Palm Beach Post

Biotech plans mapped out for Briger tract Palm Beach Post,  United States - 1 hour ago Post coverage of the growth in biotechnology in PB County and the TCoast. The so-called Briger tract is vacant land across Donald Ross Road from Florida ...

Stephen Hurly, Mark Schoenebaum, Robyn Karnauskas, Greg Tronto ... - BioRegion News

Stephen Hurly, Mark Schoenebaum, Robyn Karnauskas, Greg Tronto ... BioRegion News, NY - 2 hours ago Hurly has been named a managing director, focusing on publicly traded companies and privately held businesses in the healthcare, biotechnology and ...

Baby Guaranteed Never To Get Hereditary Breast Cancer - Boston Channel.com

Baby Guaranteed Never To Get Hereditary Breast Cancer Boston Channel.com,  USA - 2 hours ago His genetics gave him an 85 percent risk of developing colon cancer. a Ia ve seen what this disease can do, first hand. I've held my mother's hand while she ...

Bavarian Nordic Files Patent Infringement Suit Against Oxford BioMedica

KVISTGARD, Denmark, June 30 /PRNewswire-FirstCall/ -- Bavarian Nordic has filed a patent infringement suit against Oxford BioMedica plc, Biomedica, Inc., and Oxford BioMedica Ltd., in the United States District Court of the Southern District of California.

Bavarian Nordic owns several United States patents relating to an attenuated strain of the company's core technology, MVA-BN(R), which is the basis for its innovative smallpox vaccine, IMVAMUNE(R). MVA-BN(R) also holds promise as a vector for delivering recombinant vaccines.

Bavarian Nordic asserts three patents as a basis for its infringement action, which are U.S. Patent No. 6,761,893, U.S. Patent No. 6,913,752 and U.S. Patent No. 7,335,364.

The claim in this case is that the defendants have infringed Bavarian Nordic's patents by commercializing the patented technology in ways that have yielded large payments from Sanofi-Aventis under the agreement between them for the development and commercialization of TroVax(R).

The legal action versus Oxford BioMedica does not change Bavarian Nordic's previous announced financial guidance for 2008.

Anders Hedegaard, President & CEO of Bavaran Nordic, said: "The initiation of this infringement action is a necessary step to enforce our intellectual property rights. We have built a strong patent portfolio on the MVA technology, which we seek to utilize to expand and support our business through licensing agreements. However if these cannot be obtained, we will vigorously defend our IP position to prevent infringement."

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN(R) is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com/

Bavarian Nordic A/S

CONTACT: Contact: Anders Hedegaard, President & CEO, Telephone:
45-23-20-30-64

Evolutionary origin of mammalian gene regulation unravelled 150 ... - Cambridge Network

Evolutionary origin of mammalian gene regulation unravelled 150 ... Cambridge Network, UK - 43 minutes ago The findings, reported online in Nature Genetics, have provided new insights into the evolution of genomic or parental imprinting and epigenetic regulation ...

What to Expect on the Fringe - io9

What to Expect on the Fringe io9, CA - 36 minutes ago (A road sign helpfully tells us that Massive Dynamics "does everything," but in the episode they mostly do creepy things with genetics and cool things with ...

Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children

PARIS, June 30 /PRNewswire/ -- Five years after the identification of the gene responsible for progeria, a rare disease causing accelerated and premature ageing, a team of Spanish and French researchers (Carlos Lopez-Otin and coll. - University of Oviedo - and Nicolas Levy and coll. - Inserm/AP-HM, Marseille, France) have successfully demonstrated a treatment for the disease, using mice. This treatment, combining two existing pharmacological molecules, should slow down the progression of this disease which has hitherto remained untreatable.

Subject to the authorisation of health agencies, this treatment could very soon be tested on 15 children in Europe. This represents a major advance for the families affected by this disease and - more generally - for the understanding of the normal ageing process.

From identification of the gene to the development of treatment and the projected clinical protocol, this work - published in the review Nature Medicine - has received the financial backing of the Association Francaise contre les Myopathies (Muscular Dystrophy Association) thanks to French Telethon donations.

The treatment recently validated in mice is based on a combination of two existing pharmacological molecules: statins (indicated for the treatment and prevention of atherosclerosis and cardiovascular risks) and aminobisphosphonates (indicated for the treatment of osteoporosis). The Franco-Spanish researchers have demonstrated that this treatment attenuated the effects of the disease and significantly raised life expectancy.

As previously demonstrated by Nicolas Levy's team - which originally identified the gene in 2003 - progeria is due to the accumulation in the cells of a truncated protein, progerin, whose toxicity is linked to the presence of a fatty acid which remains fixed to the protein (whilst it is eliminated in normal cells). In order to inhibit or block the toxicity of progerin, the researchers explored the path of synthesis of this fatty acid. In fact, pharmacological molecules are known to block certain stages in this path of synthesis.

After several attempts they noted that a combination of a statin and an aminobisphosphonate could prevent the fixation of the fatty acid to the progerin, and thus reduce its toxicity. The progerin being less toxic, the disease develops more slowly.

Following these encouraging results, a clinical protocol based on this treatment piloted by Nicolas Levy in Marseille (France) is about to start up. It should last 3 years and will concern 15 of the 25 children affected by progeria in Europe. The aim of this protocol is to slow down the progression of the disease and, if possible, prolong the life expectancy - at present very limited - of the children affected.

Article published in Nature Medicine : http://dx.doi.org/10.1038/nm.1786

AFM-Association Francaise contre les Myopathies

CONTACT: Press Contacts : AFM : Estelle Rozine Assaf -
33-1-69-47-12-78, presse@afm.genethon.fr ; Inserm : Priscille Riviere -
33-1-44-23-60-97, presse@inserm.fr .

Invitrogen and the Genome Quebec and Montreal Heart Institute ... - Business Wire (press release)

Invitrogen and the Genome Quebec and Montreal Heart Institute ... Business Wire (press release), CA - 1 hour ago MHI researchers also contribute to the advancement of knowledge and medical applications in the fields of genomics (in particular in disease gene discovery ...

Vote will decide future direction of meat industry - National Business Review

Vote will decide future direction of meat industry National Business Review, New Zealand - 2 hours ago Farmers will be advised on what animal genetics, grass and fodder plants to use, and how to manage their pastures. Wrightson will purchase the stock. ...

Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology

PITTSBURGH, June 30 /PRNewswire/ -- Cellumen, Inc., the Cellular Systems Biology Company, announced today the initiation of a research collaboration with the National Center for Toxicology Research (NCTR), a research center of the Food and Drug Administration (FDA). Under the agreement, Cellumen will use its proprietary CellCiphr(R) toxicity risk assessment technology to profile blinded samples of known liver toxicity compounds including both failed and marketed drugs for the NCTR. The NCTR will incorporate the knowledge generated by Cellumen to develop a liver toxicity knowledge base. Cellumen will use the profiling data and compound safety data from the collaboration to further develop the diversity in the CellCiphr database and the types of cell panels, as well as to advance the classifier informatics tools.

"Failure to predict human toxicity among drug candidates early in the discovery/development process is a leading challenge for the pharmaceutical industry," stated D. Lansing Taylor, Ph.D., CEO of Cellumen. "Patients demand and deserve safe and effective drugs, while pharmaceutical companies are increasingly challenged to profitably meet that demand. Cellumen's vision is working toward the goal of replacing animal testing with a human in vitro system in order to facilitate the development of safer, more effective drugs," added Dr. Taylor.

By applying CellCiphr toxicity profiling early in the discovery and lead optimization phases, drug companies will accurately identify compounds with high human toxic liabilities. Actions can be taken to either de-prioritize high-risk compounds, or remove high-risk compounds from a lead series that ultimately would prove to be toxic. Cellumen is at the forefront of drug safety profiling services to aid in predicting drug toxicity early in the discovery/development process.

About Cellumen:

Cellumen is the leading innovator in cellular systems biology (CSB(TM)) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen's CSB solutions are driving "Discovery Toxicology" by addressing the full complexity of disease and safety. Leading global organizations such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, NIH and top pharmaceutical companies partner with Cellumen.

About CellCiphr(R):

CellCiphr is the only cell-based assay solution combining tissue-specific cells, multiplexed functional biomarkers, advanced classifiers, and a compound reference library in order to allow drug developers to accurately identify drug candidates that have high efficacy and low toxicity. CellCiphr is capable of analyzing greater than 10 functional biomarkers per assay that are used as sentinels for analysis of mechanism of action and toxicity of new compounds applied to both rodent and human cells.

Cellumen, Inc.

CONTACT: Donald P. Taylor, Senior Director, Marketing & Corporate
Development, Cellumen, Inc., 1-412-423-2284, don.taylor@cellumen.com

Piper Jaffray Would Be Buyers of Myriad Genetics (MYGN) On Today's ... - StreetInsider.com (subscription)

Piper Jaffray Would Be Buyers of Myriad Genetics (MYGN) On Today's ... StreetInsider.com (subscription), MI - 1 hour ago Piper Jaffray lowered their price target on Myriad Genetics Inc. (Nasdaq: MYGN) from 9 to 6 after Alzheimer's drug Flurizan failed in a Phase 3 study, ...

Thermo Fisher Scientific Adds New Tools to Stem Cell Research Platform - PharmaLive.com (press release)

Thermo Fisher Scientific Adds New Tools to Stem Cell Research Platform PharmaLive.com (press release), PA - 52 minutes ago CET is a biotechnology tissue engineering company, which combines expertise in stem cell science, tissue engineering and preclinical drug discovery ...

Cultivating clusters - Mainebiz Daily

Cultivating clusters Mainebiz Daily - 35 minutes ago Measuring and controlling devices, biomedical research, green products, new media and bioinformatics have all emerged as a potentiala clusters, according to ...

HairDX Selling Genetic Baldness Test To Physicians Only - Business Wire (press release)

HairDX Selling Genetic Baldness Test To Physicians Only Business Wire (press release), CA - 1 hour ago (BUSINESS WIRE)--Pharmagenomics innovator HairDX, LLC (www.hairdx.com), today announced that it will only offer its genetic tests for predicting the risk of ...

Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine

BEIJING, June 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. , a leading provider of vaccines in China, today announced the initiation of volunteer enrollment in its Phase II clinical trial for its split pandemic influenza vaccine. The preliminary results from this study are expected to be available in early 2009.

The randomized and double-blind trial is expected to enroll 210 adolescents, between the ages of 12 to 17, who will receive doses of 10ug, 15ug or 30ug, and 140 children, between the ages of 3 to 11, who will receive doses of 10ug or 15ug. Volunteers will be followed for two months with safety and immunogenicity data collected for the assessment of the vaccine.

Mr. Weidong Yin, Chairman, President and CEO, commented, ''Split influenza vaccine is believed to cause less adverse reactions in children compared to whole-viron influenza vaccine. Sinovac's split pandemic influenza vaccine aims at protecting the pediatric and adolescent population. Based on the positive safety results of the Phase I trial, the Phase II study will be conducted to further collect the vaccine's safety data in children and adolescents, as well as assessing the immunogenicity of different doses.''

Sinovac received approval from the China State Food and Drug Administration (SFDA) in April 2007 to conduct clinical trials for two types of the H5N1 vaccine, namely Phase Ib and II trials of the H5N1 whole viron vaccine and Phase I and Phase II trials of the H5N1 split vaccine. In December 2007, Sinovac reported positive top-line results from the completed Phase II clinical trial of Panflu(TM), its pandemic influenza (H5N1) whole viron inactivated vaccine. In April 2008, Panflu(TM) was granted a production license by the China State Food and Drug Administration (SFDA). Panflu(TM) is the first and only approved vaccine available in China against the H5N1 influenza virus.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com/ . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: 86-10-8289-0088 x871 Fax: 86-10-6296-6910 Email: info@sinovac.com Investors/Media: Stephanie Carrington / Janine McCargo The Ruth Group Tel: 1-646-536-7017/7033 Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com

Sinovac Biotech Ltd.

CONTACT: Helen G. Yang of Sinovac Biotech Ltd., 86-10-8289-0088 x871, or
86-10-6296-6910, or info@sinovac.com; or Investors/Media: Stephanie
Carrington / Janine McCargo, both of The Ruth Group, 1-646-536-7017/7033, or
scarrington@theruthgroup.com / jmccargo@theruthgroup.com

Web site: http://www.sinovac.com/

Genetics, Environment Shape Sexual Behavior - HealthCentral.com

Genetics, Environment Shape Sexual Behavior HealthCentral.com, VA - 50 minutes ago MONDAY, June 30 (HealthDay News) -- Genetics and random environmental factors each play a major role in determining both gay and heterosexual behavior, ...

New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration

SILVER SPRING, Md., June 30 /PRNewswire-FirstCall/ -- United Therapeutics Corporation and its wholly-owned subsidiary, Lung Rx, Inc., announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of an inhaled formulation of treprostinil (ITRE) for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disease. The submission starts a 60-day period during which the FDA will examine the application for completeness. If the FDA accepts the ITRE NDA for review, then it is expected to be subject to the standard 10- to 12-month review period before an action letter is issued.

"We believe that an inhaled formulation of treprostinil will be a very desirable option for PAH patients," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The completion of the NDA filing is a huge milestone in United Therapeutics' quest to develop as many formulations of treprostinil as possible to create better, more convenient therapies to treat the debilitating effects of PAH along the full spectrum of the disease."

The ITRE NDA is principally supported by data from the TRIUMPH-1 Phase III clinical trial.

About TRIUMPH-1

TRIUMPH-1 (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension), was a randomized, double-blind, placebo- controlled trial of patients with PAH. ITRE is prepared once per day and administered in four daily inhalation sessions using the NEBU-TEC Optineb(TM) ultrasonic nebulizer, with each inhalation session taking approximately 1-2 minutes.

The TRIUMPH-1 clinical trial is one of the first pivotal trials to assess the incremental benefit of an add-on therapy in PAH patients who are already receiving an approved background therapy. The study population consisted of 235 patients who were optimized on an approved oral therapy for PAH, either bosentan (Tracleer(R)), an endothelin receptor antagonist, or sildenafil (Revatio(R)), a phosphodiesterase-5 inhibitor. The majority of patients were New York Heart Association (NYHA) Class III (~98%) of varied etiologies, including idiopathic or familial PAH (~60%), collagen vascular disease associated PAH (~30%), and PAH associated with HIV, anorexigens or other associated conditions (~10%).

The primary efficacy endpoint of the TRIUMPH-1 clinical trial was the change in six-minute walk (6MW) distance at 12 weeks measured at peak exposure, defined by the trial protocol as 10-60 minutes after administration of ITRE relative to baseline. Analysis of the TRIUMPH-1 clinical trial results confirmed an improvement in median 6MW distance of approximately 20 meters (p<0.0005 at peak exposure, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial's pre-specified statistical analysis plan), in patients receiving ITRE as compared to patients receiving only background therapy. In addition, the 6MW distance at week 12 relative to baseline at trough exposure was also significantly improved, with an estimated treatment effect of approximately 14 meters (p<0.007). Secondary endpoints related to quality of life and change in NT pro-BNP, a plasma biomarker of cardiac function, were also significantly improved in the ITRE group as compared to the group receiving only background therapy (p<0.05). Other secondary efficacy measures, including change in Borg Dyspnea Score (shortness of breath test), NYHA functional class, signs and symptoms score, and time to clinical worsening, were not significantly different between the ITRE and background therapy only groups. Safety findings were typically those associated with the well-known vasodilatory side effects of prostacyclin and its analogs (e.g., headache, nausea, dizziness, flushing) and those commonly associated with the inhalation route of administration (e.g., cough and throat irritation). These side effects were mostly mild or moderate in severity and were not dose-limiting in the majority of patients treated with ITRE.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

About Lung Rx

Lung Rx is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of innovative therapeutic products.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include our expectation that the ITRE NDA will be subject to a 10- to 12-month review period and our belief that ITRE will be a desirable option for PAH patients once it has been approved for marketing. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, which could cause actual results to differ materially from anticipated results. These risks and uncertainties include, among others, the failure of ITRE and the nebulizers used to administer ITRE to receive regulatory approvals on the schedule expected; the uncertainties of launching a new product on a global scale following receipt of regulatory approvals, if received, due to misestimates of the time and resources required to do so, or for other reasons; the failure of ITRE to receive favorable pricing or reimbursement; the possible inaccuracies of our analysis with respect to the TRIUMPH-1 preliminary trial results and market opportunity; and the inability of ourselves and our suppliers to manufacture ITRE and the nebulizers used to administer the drug in accordance with all applicable regulatory requirements and in sufficient quantity to support patient demand. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward- looking statements. We are providing this information as of June 30, 2008, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

United Therapeutics Corporation

CONTACT: Andrew Fisher of United Therapeutics Corporation,
1-202-483-7000, Afisher@unither.com

Web site: http://www.unither.com/

Transcriptional profiling of the pea shoot apical meristem reveals ... - 7thSpace Interactive (press release)

Transcriptional profiling of the pea shoot apical meristem reveals ... 7thSpace Interactive (press release), NY - 1 hour ago In addition, the availability of a plethora of developmental mutants makes pea an ideal crop legume for genomics studies. This study aims to utilise ...

TriMEDB: A database to integrate transcribed markers and ... - 7thSpace Interactive (press release)

TriMEDB: A database to integrate transcribed markers and ... 7thSpace Interactive (press release), NY - 35 minutes ago Therefore, informatics applications and a semantic knowledgebase of genome-wide markers are required for the integration of information on and further ...

Tobira Therapeutics Inc. Announces Senior Management Team - Senior management team possessing over 130 years of cumulative expertise -

PRINCETON, N.J. and SAN DIEGO, June 30 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the organization of the company's senior management team. Tobira Therapeutics has been led since its inception in 2006 by James Sapirstein, RPh, MBA as Chief Executive Officer and President. Joining James is Sandra Palleja, MD, Executive Vice-President and Chief Medical Officer, Angeline Shashlo, RPh, Senior Vice-President Regulatory Affairs and Quality Assurance, and Jay Rheingold, PhD, Vice-President Chemistry Manufacturing and Controls. These additions continue to build the management team with world-class pharmaceutical development experts. "With this senior management team Tobira Therapeutics has more than 130 years of combined pharmaceutical experience, with the majority focused in biotech companies or HIV compounds. We are perfectly positioned to bring novel molecules to market that will play an important role in the treatment of HIV infection".

Dr. Palleja is the Chief Medical Officer, responsible for the overall clinical development of the Tobira Therapeutics portfolio. Sandra joined Tobira from Shionogi USA, where she lead numerous clinical programs as Vice President of Clinical Development in several therapeutic categories including an HIV joint venture with GSK. Prior to her years at Shionogi, Sandra gained additional experience from both Triangle Pharmaceutics and Hoffman-LaRoche, where she helped develop a variety of antivirals for HIV and hepatitis including FTC, DAPD, ganciclovir, and saquinavir. Prior to her career in industry, she was the Director of the Infectious Diseases Clinic at St. Vincent's Hospital and Medical Center of New York City during the mid to late 90's. Prior to her years at St. Vincent's, Sandra was an Associate Professor of Medicine, served as the Primary Care Liason to the AIDS Team at the Albert Einstein College of Medicine and Bronx Municipal Hospital Center. From 1989-1993, she also served as Consultant to the AIDS Institute, NYSDOH and the Federally Funded Ryan White Title III Program. She earned her MD from Boston University School of Medicine.

Ms. Shashlo joined Tobira from Incyte Corporation where she held a similar role as the VP of Regulatory Affairs and Quality Assurance. Prior to Incyte, Angie spent several years working with start-up companies such as Genaera, Vitagen and Ligand in a variety of roles including Project Management. Angeline spent many years working for larger pharmaceutical companies such as Wyeth and Upjohn during the first half of her 25-year career in positions of increasing responsibility. Angie received her Bachelor of Science in Pharmacy from the University of Michigan.

Dr. Rheingold brings over 29 years of experience in new product scale-up, formulation development and manufacturing to Tobira Therapeutics. Jay has successfully brought over 25 products to market during his tenure at Lederle, Hoffman-LaRoche, Bristol-Myers Squibb and Organon pharmaceutical companies. He received his doctorate in Pharmaceutical Sciences from the University of Connecticut. Jay joins Tobira from Barrier Therapeutics, where he held the position of Vice-President.

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

Contact: Tobira Therapeutics Inc. James Sapirstein CEO and President Tobira Therapeutics, Inc. jsapirstein@tobiratherapeutics.com Tel: 609-897-1102 http://www.tobiratherapeutics.com/

Tobira Therapeutics Inc.

CONTACT: James Sapirstein CEO and President or Tobira Therapeutics,
Inc., 1-609-897-1102, jsapirstein@tobiratherapeutics.com

Web site: http://www.tobiratherapeutics.com/

Reaching for individualized medicine - Ars Technica

Reaching for individualized medicine Ars Technica, MA - 37 minutes ago A combination of global projects and advancing technology has dropped the cost of genomics research, and it enables scientists to "light up the whole ...

Mesoblast Limited (ASX:MSB) Equity Report By OzEquities - ABN Newswire (press release)

Mesoblast Limited (ASX:MSB) Equity Report By OzEquities ABN Newswire (press release), Australia - 1 hour ago Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, ...

Nucletron Appoints New Chief Executive Officer

VEENENDAAL, The Netherlands, June 30 /PRNewswire/ --

- Jos Lamers Brings Years of International Senior Management Experience to His New Role

VEENENDAAL, The Netherlands, June 30 /PRNewswire/ --

Nucletron announced today the appointment of Jos Lamers as its new chief executive officer. The appointment marks the next phase for the company following its successful management buy-out from Delft Instruments in August 2007, which created an independent company fully dedicated to radiation oncology.

Since its inception in 1974, Nucletron has operated several entities in the field of radiation oncology throughout the world. The consolidation of the various entities into one focused company has further established Nucletron as a leader in this rapidly changing field.

Jos Lamers, a highly experienced international business executive, has a proven track record in life sciences and business-to-business fields. Prior to joining Nucletron, he held senior management and board positions at Numico, Europe's top manufacture of baby and infant related food products, and currently is a member of the Executive Board at Eurofins Scientific, the leading international laboratory group offering quality testing and support services.

"I am excited to join Nucletron as the CEO of this global leader in radiation oncology," said Jos Lamers. "The strong management team and innovative approach to product development and delivery allow me to look forward to driving its performance further."

With the appointment of Jos Lamers as CEO, the managing board of Nucletron is complete, with Jeroen Cammeraat as chief operating officer and Jan Sigger as chief financial officer.

Headquartered in the Netherlands, Nucletron delivers customized solutions to more than 3,000 institutions in more than 120 countries, equating to global sales of EUR120 million (US80 million), with operating profit levels that rank in the upper quartile of the industry. Worldwide, Nucletron has offices in 16 countries, including a production and R&D facility in The Netherlands, R&D centers in Uppsala, Sweden and Oslo, Norway and sales, marketing, service and support operations in Europe, Asia, Australia and North America.

The chairman of the supervisory board of Nucletron, Rob Westerhof, who has held senior positions in Asia and in the USA for Philips Medical Systems and Philips Electronics, commented on the appointment, "We are very pleased to have Jos Lamers join Nucletron as CEO. With his broad international experience I am sure that he will make a significant contribution to the company's performance."

About Nucletron

Nucletron is a knowledge-based leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.

VEENENDAAL, The Netherlands, June 30 /PRNewswire/ --

Nucletron

Nucletron B.V., PO Box 930, 3900 AX Veenendaal, The Netherlands, Phone 31(0)318-557133. Media Contact: Danielle Davis, 1-443-834-6725, ddavis@rosecomm.com .

Science, Notes & News - Louisville Courier-Journal

Science, Notes & News Louisville Courier-Journal, KY - 1 hour ago ... a joint biotech venture of Australia's Molecular Plant Breeding Cooperative Research Centre and New Zealand rural services group PGG Wrightson Genomics, ...

Yes, we may have no bananas - Fort Worth Star Telegram

Yes, we may have no bananas Fort Worth Star Telegram, TX - 1 hour ago The final piece of the banana pricing equation is genetics. Unlike apple and orange growers, banana importers sell only a single variety of their fruit, ...

The Big Screen Bulletin 06.30.08: Where Computers Die and Critics Fly - 411mania.com

The Big Screen Bulletin 06.30.08: Where Computers Die and Critics Fly 411mania.com, TX - 1 hour ago A science fiction genre that focuses on biotechnology and subversives. The biopunk movement is a small intellectual and cultural movement, which encompasses ...